Group items tagged

People are advised to be mindful of medications that may cause sun reactions, and to watch out for dodgy hay fever treatments and fake weight loss pens. For those traveling abroad, the MHRA advises considering the suitability of medicines available to reduce the risk of contracting tropical diseases. Dr Alison Cave, Chief Safety Officer at the MHRA, said: "The summer is an exciting time for many of us, as we take time off to travel and enjoy the warmer weather. "But it is important to understand what this time of year means for our medicines and medical devices, and take the precautions necessary to use products safely and protect ourselves." Watch out for dodgy hay fever treatments Millions of Britons suffer from hay fever symptoms in the summer. The MHRA advises consulting a healthcare professional to find the best treatment for your symptoms. People are also warned to be cautious of medicines advertised as hay fever treatments but not approved for use in the UK, such as Kenalog. This is a prescription-only steroid injection licensed as a medicine for other conditions, but not for the treatment of hay fever.

Jackie Giltrow and Jose Moss have been appointed as Chair and Vice-Chair of the Community Pharmacy Patient Safety group, respectively, bringing with them a wealth of experience and expertise in pharmacy practice. Supported by the National Pharmacy Association (NPA) and hosted by the Company Chemists' Association (CCA), the CPPSG serves as a collaborative platform for large community pharmacy organisations to openly share and learn from each other's experiences. A CPPSG Chair now, Jackie Giltrow, Clinical Governance Lead at Paydens Limited is a seasoned pharmacist and expert in risk management and patient safety. With nine years of experience as a member of the CPPSG, Giltrow's appointment represents a continuation of her longstanding dedication to advancing patient safety initiatives within community pharmacy settings.

U.S. Customs and Border Protection (CBP) officers at the port of Cincinnati seized two unapproved shipments of weight loss drugs, including one from a UK pharmacy, last month. On 5 October, CBP officers seized a shipment declared as "cosmetic weight loss product" and found containing Mounjaro injectable pens of multiple doses (2.5mg, 5mg, and 7mg). The shipment, arriving from a UK pharmacy and heading to a residence in Ohio, violated the Federal Food, Drug, and Cosmetic Act (FDCA), according to a U.S. Customs and Border Protection report. Cincinnati CBP officers on 14 October intercepted another shipment, which was also destined for an Ohio residence. This shipment from Hong Kong contained 20 vials of Semaglutide 10 mg and 150 Tirzepatide 30 mg, with a domestic value of $45,450. LaFonda D. Sutton-Burke, Director of Field Operations-Chicago, stated that seizures involving these types of unapproved medications are a common occurrence that her officers see on a regular basis.

Omnicell UK & Ireland, a leading provider of pharmacy and nursing care automation solutions, has announced a strategic partnership with Gollmann to integrate the German manufacturers' advanced robotic storage and dispensing technology into its retail and central pharmacy solutions portfolio. This collaboration aims to address the increasing pressure on community pharmacies and hospitals to enhance patient safety and meet strict regulatory standards while improving operational efficiency. By combining Omnicell's extensive expertise with Gollmann's innovative technology, the partnership intends to streamline real-time medication dispensing and loading activities, thereby delivering improved workflows and outcomes. Nnamdi Njoku, executive vice president and chief operating officer of Omnicell, highlighted the company's commitment to providing software and automation solutions to ensure "safe, efficient medication and supply management across the healthcare continuum." "Through strategic relationships with technology leaders like Gollmann, and others announced earlier this month with TrackTraceRX, LSPedia, and Follett, we are growing our solutions portfolio as we seek to meet the evolving needs of our global customers, while being focused on driving greater efficiency and working to improve patient safety across hospital and retail settings," he said.

The Medicines and Healthcare products Regulatory Agency (MHRA) has launched a consultation on the reclassification of codeine linctus to a prescription-only medicine after considering multiple Yellow Card reports for its opioid effects, rather than for its intended use as a cough suppressant. This medication is currently licensed as a pharmacy medicine, which means that it is available to purchase over the counter in pharmacies. If reclassified as a prescription-only medicine, all strengths of codeine linctus will only be available upon presentation of a prescription. Dr Alison Cave, MHRA Chief Safety Officer, said: "Codeine linctus is an effective medicine, but as it is an opioid, its misuse and abuse can have major health consequences. Every response received will help us to develop a broader view on whether codeine linctus should be restricted to prescription-only status. We want to hear from members of the public, health professionals and others who would be affected by this potential change so we can make a properly considered decision for the benefit of patients, carers, and healthcare professionals across the UK.

It has been reported that several Austrians have been taken to the hospital after injecting fake Ozempic, as confirmed by health regulator. Austria's Federal Office for Safety in Health Care (BASG) confirmed that the patients have suffered hypoglycaemia and seizures. It is believed that the injections contained insulin instead of the weight loss drug, semaglutide. The health regulator has urged doctors and patients to verify their medication stocks.